Tumor-Associated Carbohydrate Antigen 19-9 (CA 19-9), a Promising Target for Antibody-Based Detection, Diagnosis, and Immunotherapy of Cancer.

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2024-09-04 DOI:10.1002/cmdc.202400491

Athar Nakisa, Lorenzo F Sempere, Xi Chen, Linda T Qu, Daniel Woldring, Howard C Crawford, Xuefei Huang

引用次数: 0

Abstract

Carbohydrate antigen 19-9 (CA 19-9) also known as sialyl Lewis A is a tetrasaccharide overexpressed on a wide range of cancerous cells. CA 19-9 has been detected at elevated levels in sera of patients with various types of malignancies, most prominently pancreatic ductal adenocarcinoma. After its identification in 1979, multiple studies have highlighted the significant roles of CA 19-9 in cancer progression, including facilitating extravasation and eventually metastases, proliferation of cancer cells, and suppression of the immune system. Therefore, CA 19-9 has been considered an attractive target for cancer diagnosis, prognosis, and therapy. This review discusses the synthesis of CA 19-9 antigen, elicitation of antibodies through vaccination, development of anti-CA 19-9 monoclonal antibodies, and their applications as imaging tracers and therapeutics for a variety of CA 19-9-positive cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤相关碳水化合物抗原 19-9 (CA19-9)--基于抗体的癌症检测、诊断和免疫疗法的有望靶点。

碳水化合物抗原 19-9（CA 19-9）又称 sialyl Lewis A，是一种在多种癌细胞上过度表达的四糖，在各类恶性肿瘤（最常见的是胰腺导管腺癌）患者的血清中检测到其含量升高。自 1979 年发现 CA 19-9 后，多项研究都强调了它在癌症进展过程中的重要作用，包括促进癌细胞外渗并最终转移、癌细胞增殖以及抑制免疫系统。因此，CA 19-9 被认为是癌症诊断、预后和治疗的一个有吸引力的靶点。本综述将讨论 CA 19-9 抗原的合成、通过疫苗接种激发抗体、抗 CA 19-9 单克隆抗体的开发，以及它们作为成像示踪剂和治疗各种 CA 19-9 阳性癌症的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.